Similarly, more than 50 of the common genetic BC susceptibility variants have also been shown to be associated with BC for BRCA1 and BRCA2 mutation carriers5,6,15,18,20,39–48 and their joint effects, summarised as polygenic risk scores (PRS), result in large differences in the absolute risks of developing BC for mutation carriers at the extremes of the PRS distribution49. This evidence concerns the gene BRCA2 and breast cancer.